BREAKING GROUND: LATEST INNOVATIONS AND THERAPIES IN OVARIAN CANCER TREATMENT

Abstract

Ovarian cancer (OC) stands out as the most deadly among gynecologic tumors, characterized by high morbidity and low survival rates, particularly in advanced stages. Despite extensive research efforts, the lack of effective screening tools for early detection remains a significant challenge, contributing to the poor prognosis associated with OC. The current therapeutic management of OC involves a multidisciplinary approach, including debulking surgery, chemotherapy, and infrequently, radiotherapy. Immunomodulation has recently gained attention as a potential treatment avenue for OC. Relapse rates in OC are notably high, occurring approximately every two years, leading to intensified subsequent treatments. This recurrence poses challenges such as increased toxicity, chemotherapy resistance, and elevated financial burden, negatively impacting patients' quality of life. A promising strategy to address these challenges involves pre-sensitizing cancer cells with standard therapy, aiming to achieve optimal results with minimal dosage. This review extensively explores current research, biomarkers, treatment options, and ongoing clinical trials related to OC. The focus is on summarizing recent developments in translational and clinical research, with a systematic discussion of various strategies aimed at enhancing therapeutic responses in OC.